American Association for Cancer Research
bcd-23-0056_figure_s1_suppsf1.pdf (115.33 kB)

Figure S1 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma

Download (115.33 kB)
journal contribution
posted on 2024-03-01, 10:21 authored by Rawan G. Faramand, Sae Bom Lee, Michael D. Jain, Biwei Cao, Xuefeng Wang, Kai Rejeski, Marion Subklewe, Johannes F. Fahrmann, Neeraj Y. Saini, Samir M. Hanash, Yun Pyo Kang, Darwin Chang, Paolo C. Rodriguez, Erin A. Dean, Taiga Nishihori, Bijal D. Shah, Aleksandr Lazaryan, Julio Chavez, Farhad Khimani, Javier A. Pinilla-Ibarz, Marian Dam, Kayla M. Reid, Salvatore A. Corallo, Meghan Menges, Melanie Hidalgo Vargas, Jay K. Mandula, Brian A. Holliday, Christina A. Bachmeier, Kelly Speth, Qinghua Song, Mike Mattie, Frederick L. Locke, Marco L. Davila

Figure S1 shows the serum markers associated with severe CRS and ICANS


National Institutes of Health (NIH)



A subset of patients with diffuse large B-cell lymphoma (DLBCL) treated with CD19 chimeric antigen receptor (CAR) T-cell therapy have poor clinical outcomes. We report serum proteins associated with severe immune-mediated toxicities and inferior clinical responses in 146 patients with DLBCL treated with axicabtagene ciloleucel. We develop a simple stratification based on pre-lymphodepletion C reactive protein (CRP) and ferritin to classify patients into low-, intermediate-, and high-risk groups. We observe that patients in the high-risk category were more likely to develop grade ≥3 toxicities and had inferior overall and progression-free survival. We sought to validate our findings with two independent international cohorts demonstrating that patients classified as low-risk have excellent efficacy and safety outcomes. Based on routine and readily available laboratory tests that can be obtained prior to lymphodepleting chemotherapy, this simple risk stratification can inform patient selection for CAR T-cell therapy. CAR T-cell therapy has changed the treatment paradigm for patients with relapsed/refractory hematologic malignancies. Despite encouraging efficacy, a subset of patients have poor clinical outcomes. We show that a simple clinically applicable model using pre-lymphodepletion CRP and ferritin can identify patients at high risk of poor outcomes.This article is featured in Selected Articles from This Issue, p. 80

Usage metrics

    Blood Cancer Discovery



    Ref. manager